Abstract |
Angina pectoris is one of the major syndromes against which to test the therapeutic effectiveness of any new calcium antagonist. An interim analysis of the efficacy and safety of a new dihydropyridine calcium antagonist ( PN 200-110 [ isradipine]) in patients with confirmed coronary artery disease is reported. The study was carried out in 3 centers; 50 patients of an anticipated 96 have completed the double-blind comparative phases in 3 separate studies. Preliminary results from the placebo-controlled study indicate that PN 200-110 was significantly more effective than placebo in reducing the anginal attack rate and glyceryl trinitrate consumption in the 15 patients so far enrolled. Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs. No significant change in any of the monitored safety factors was noted in any of the patients taking PN 200-110. The side-effects profile compared favorably with that of nifedipine. These interim results suggest that PN 200-110 will prove to be an effective and safe drug for the treatment of angina pectoris.
|
Authors | S H Taylor, N C Jackson, J Allen, P E Pool |
Journal | The American journal of cardiology
(Am J Cardiol)
Vol. 59
Issue 3
Pg. 123B-129B
(Jan 30 1987)
ISSN: 0002-9149 [Print] United States |
PMID | 2949583
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Calcium Channel Blockers
- Oxadiazoles
- Placebos
- Nifedipine
- Isosorbide Dinitrate
- Isradipine
|
Topics |
- Angina Pectoris
(drug therapy)
- Calcium Channel Blockers
(therapeutic use)
- Clinical Trials as Topic
- Double-Blind Method
- Exercise Test
- Female
- Humans
- Isosorbide Dinitrate
(therapeutic use)
- Isradipine
- Male
- Nifedipine
(therapeutic use)
- Oxadiazoles
(therapeutic use)
- Placebos
|